Do you want to make a comment, Ms. Vowles? No? Okay.
We are talking about rare diseases. There are few people affected in Canada, but a little more in the United States. How do you view research competition within the G7 countries, particularly with respect to large countries developing drugs?
There is competition between these countries, but the treatment and accessibility are not the same. In a country the size of Canada, there are several cases. As for you, Ms. Little, we're talking about 75 or 100 patients. How do we manage, on a global scale, to offer a service and do this research in such a way that it is profitable not for companies but for patients?